Gita Suneja

Gita Suneja

Auto-generated profile, based on publicly available information

Gita Suneja

Department of Radiation Oncology, University of Utah School of Medicine, Huntsman Cancer Institute , Salt Lake City, Utah

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2014 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
GSGita Suneja
Gita Suneja
MSMeredith S. Shiels
Meredith S. Shiels
RARory Angulo
Rory Angulo
GCGlenn E. Copeland
Glenn E. Copeland
LGLou Gonsalves
Lou Gonsalves
EEEric A. Engels
Eric A. Engels
Purpose: HIV-infected individuals with cancer have worse survival rates compared with their HIV-uninfected counterparts. One explanation may be differing cancer treatment; however, few studies have examined this. Patients and Methods: We used HIV and cancer registry data from Connecticut, Michigan, and Texas to study adults diagnosed with non-Hodgkin's lymphoma, Hodgkin's lymphoma, or cervical, lung, anal, prostate, colorectal, or breast cancers from 1996 to 2010. We used logistic regression to examine associations between HIV status and cancer treatment, adjusted for cancer stage and demographic covariates. For a subset of local-stage cancers, we used logistic regression to assess the relationship between HIV status and standard treatment modality. We identified predictors of cancer treatment among individuals with both HIV and cancer. Results: We evaluated 3,045 HIV-infected patients with cancer and 1,087,648 patients with cancer without HIV infection. A significantly higher proportion of HIV-infected individuals did not receive cancer treatment for diffuse large B-cell lymphoma (DLBCL; adjusted odds ratio [aOR], 1.67; 95% CI, 1.41 to 1.99), lung cancer (aOR, 2.18; 95% CI, 1.80 to 2.64), Hodgkin's lymphoma (aOR, 1.77; 95% CI, 1.33 to 2.37), prostate cancer (aOR, 1.79; 95% CI, 1.31 to 2.46), and colorectal cancer (aOR, 2.27; 95% CI, 1.38 to 3.72). HIV infection was associated with a lack of standard treatment modality for local-stage DLBCL (aOR, 2.02; 95% CI, 1.50 to 2.72), non–small-cell lung cancer (aOR, 2.43; 95% CI, 1.46 to 4.03), and colon cancer (aOR, 4.77; 95% CI, 1.76 to 12.96). Among HIV-infected individuals, factors independently associated with lack of cancer treatment included low CD4 count, male sex with injection drug use as mode of HIV exposure, age 45 to 64 years, black race, and distant or unknown cancer stage. Conclusion: HIV-infected individuals are less likely to receive treatment for some cancers than uninfected people, which may affect survival rates.

17 May 2016 in Cancer
Verified
Journal Article
Open access
PDF file
GSGita Suneja
Gita Suneja
CLChun Chieh Lin
Chun Chieh Lin
ESEdgar P. Simard
Edgar P. Simard
XHXuesong Han
Xuesong Han
EEEric A. Engels
Eric A. Engels
AJAhmedin Jemal
Ahmedin Jemal
BACKGROUND: Patients with cancer who are infected with the human immunodeficiency virus (HIV) are less likely to receive cancer treatment compared with HIV‐uninfected individuals. However, to the authors' knowledge, the impact of insurance status and comorbidities is unknown.METHODS: Data from the National Cancer Data Base were used to study nonelderly adults diagnosed with several common cancers from 2003 to 2011. Cancer treatment was defined as chemotherapy, surgery, radiotherapy, or any combination during the first course of treatment. Multivariate logistic regression was used to examine associations between HIV status and lack of cancer treatment, and identify predictors for lack of treatment among HIV‐infected patients.RESULTS: A total of 10,265 HIV‐infected and 2,219,232 HIV‐uninfected cases were included. In multivariate analysis, HIV‐infected patients with cancer were found to be more likely to lack cancer treatment for cancers of the head and neck (adjusted odds ratio [aOR], 1.48; 95% confidence interval [95% CI], 1.09‐2.01), upper gastrointestinal tract (aOR, 2.62; 95% CI, 2.04‐3.37), colorectum (aOR, 1.70; 95% CI, 1.17‐2.48), lung (aOR, 2.46; 95% CI, 2.19‐2.76), breast (aOR, 2.14; 95% CI, 1.16‐3.98), cervix (aOR, 2.81; 95% CI, 1.77‐4.45), prostate (aOR, 2.16; 95% CI, 1.69‐2.76), Hodgkin lymphoma (aOR, 1.92; 95% CI, 1.66‐2.22), and diffuse large B‐cell lymphoma (aOR, 1.82; 95% CI, 1.65‐2.00). Predictors of a lack of cancer treatment among HIV‐infected individuals varied by tumor type (solid tumor vs lymphoma), but black race and a lack of private insurance were found to be predictors for both groups.CONCLUSIONS: In the United States, HIV‐infected patients with cancer appear to be less likely to receive cancer treatment regardless of insurance and comorbidities. To the authors' knowledge, the current study is the largest study of cancer treatment in HIV‐infected patients with cancer in the United States and provides evidence of cancer treatment disparities even after controlling for differences with regard to insurance status and comorbidities. Further work should focus on addressing differential cancer treatment. Cancer 2016;122:2399–2407. © 2016 American Cancer Society.

1 May 2015 in Journal of Oncology Practice
Verified
Journal Article
Closed access
GSGita Suneja
Gita Suneja
MBMatthew Boyer
Matthew Boyer
BYBaligh R. Yehia
Baligh R. Yehia
MSMeredith S. Shiels
Meredith S. Shiels
EEEric A. Engels
Eric A. Engels
JLJudith A. Long
Judith A. Long
Provider-level factors are associated with delivery of nonstandard cancer treatment to HIV-infected patients. Policy change, provider education, and multidisciplinary collaboration are needed to improve access to cancer treatment.

1 January 2017 in Brachytherapy
Verified
Journal Article
Closed access
GSGita Suneja
Gita Suneja
DBDerek Brown
Derek Brown
ACAmy Chang
Amy Chang
BEBeth Erickson
Beth Erickson
EFElena Fidarova
Elena Fidarova
DGDavid Gaffney
David Gaffney

1 April 2018 in Journal of Neurosurgery
Verified
Journal Article
Closed access
JFJonathan Frandsen
Jonathan Frandsen
AOAndrew Orton
Andrew Orton
RJRandy Jensen
Randy Jensen
HCHoward Colman
Howard Colman
ACAdam L. Cohen
Adam L. Cohen
GSGita Suneja
Gita Suneja
OBJECTIVE: The authors compared presenting characteristics and survival for patients with gliosarcoma (GS) and glioblastoma (GBM). Additionally, they performed a survival analysis for patients who underwent GS treatments with the hypothesis that trimodality therapy (surgery followed by radiation and chemotherapy) would be superior to nontrimodality therapy (surgery alone or surgery followed by chemotherapy or radiation).METHODS: Adults diagnosed with GS and GBM between the years 2004 and 2013 were queried from the National Cancer Database. Chi-square analysis was used to compare presenting characteristics. Kaplan-Meier, Cox regression, and propensity score analyses were employed for survival analyses.RESULTS: In total, data from 1102 patients with GS and 36,658 patients with GBM were analyzed. Gliosarcoma had an increased rate of gross-total resection (GTR) compared with GBM (19% vs 15%, p < 0.001). Survival was not different for patients with GBM (p = 0.068) compared with those with GS. After propensity score analysis for GS, patients receiving trimodality therapy (surgery followed by radiation and chemotherapy) had improved survival (12.9 months) compared with those not receiving trimodality therapy (5.5 months). In multivariate analysis, GTR, female sex, fewer comorbidities, trimodality therapy, and age < 65 years were associated with improved survival. There was a trend toward improved survival with MGMT promoter methylation (p = 0.117).CONCLUSIONS: In this large registry study, there was no difference in survival in patients with GBM compared with GS. Among GS patients, trimodality therapy significantly improved survival compared with nontrimodality therapy. Gross-total resection also improved survival, and there was a trend toward increased survival with MGMT promoter methylation in GS. The major potential confounder in this study is that patients with poor functional status may not have received aggressive radiation or chemotherapy treatments, leading to the observed outcome. This study should be considered hypothesis-generating; however, due to its rarity, conducting a clinical trial with GS patients alone may prove difficult.

15 January 2019 in Cancer
Verified
Journal Article
Open access
PDF file
KCKelsey L. Corrigan
Kelsey L. Corrigan
KWKevin C. Wall
Kevin C. Wall
JBJohn A. Bartlett
John A. Bartlett
GSGita Suneja
Gita Suneja
Background: People with HIV (PWHIV) have improved survival because of the advent of antiretroviral therapy. Consequently, PWHIV experience higher rates of non‐acquired immunodeficiency syndrome‐defining malignancies (NADMs). Previous studies have demonstrated worsened cancer‐specific survival in PWHIV, partly because of advanced cancer stage at diagnosis. The objective of the current systematic review was to evaluate screening disparities for NADMs among PWHIV. Methods: The PubMed, Cochrane, EMBASE, and ClinicalTrials.gov databases were searched from January 1, 1996 through April 10, 2018 to identify studies related to screening disparities for NADMs among PWHIV. Eligibility criteria included any study performed in a high‐income country that compared screening for NADMs by HIV status. After title/abstract screening and full‐text review, articles that met eligibility criteria were analyzed. Results: Of 613 unique articles identified through the search, 9 studies were analyzed. Three studies addressed breast cancer screening, 4 addressed colorectal cancer screening, and 2 addressed prostate cancer screening. Five of the reviewed studies demonstrated that PWHIV were less likely to receive indicated cancer screenings compared with the general population, whereas 3 indicated that screening proportions were higher among PWHIV, and 1 demonstrated that screening proportions were comparable. In most of the studies, PWHIV who had regular access to health care were more likely to undergo cancer screening. Conclusions: The available evidence does not uniformly confirm that PWHIV are less likely to receive cancer screening. Social determinants of health (insurance status, access to health care, education, income level) were associated with the receipt of appropriate cancer screening, suggesting that these barriers need to be addressed to improve cancer screening in PWHIV.